Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
University of Wisconsin Clinical Science Center
mi
from
Madison, WI
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
University of Wisconsin Clinical Science Center
mi
from
Madison, WI
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Bruxelles,
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
Status: Enrolling
Updated:  3/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
Status: Enrolling
Updated: 3/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Arizona Oncology Associates, P.C.,
mi
from
Phoenix, AZ
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Arizona Oncology Associates, P.C.,
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Florida Cancer Specialists
mi
from
Ft. Myers, FL
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Florida Cancer Specialists
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Florida Cancer Specialists, Site #179
mi
from
St. Petersburg, FL
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Florida Cancer Specialists, Site #179
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Dana Faber Cancer Institute
mi
from
Boston, MA
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Dana Faber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Nebraska Cancer Specialists
mi
from
Omaha, NE
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
New York Oncology Hematology
mi
from
New York, NY
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
New York Oncology Hematology
mi
from
New York, NY
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Waverly Hematology Oncology
mi
from
Cary, NC
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Waverly Hematology Oncology
mi
from
Cary, NC
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Duke University
mi
from
Durham, NC
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Texas Oncology - Baylor
mi
from
Dallas, TX
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Texas Oncology - Baylor
mi
from
Dallas, TX
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Texas Oncology
mi
from
Houston, TX
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Texas Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
The Mayo Clinic
mi
from
Rochester, MN
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Mt. Sinai Hosp., Marvette Koffler Breast Center
mi
from
Toronto,
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Mt. Sinai Hosp., Marvette Koffler Breast Center
mi
from
Toronto,
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
DCSNO Carrollton Medical Center
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
DCSNO Carrollton Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
DCSNO St Cecelia Medical Center
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
DCSNO St Cecelia Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
EXCELth - Ida Hymel Community Health Center
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
EXCELth - Ida Hymel Community Health Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
Tulane Communty Health Center at Covenant House
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
Tulane Communty Health Center at Covenant House
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
Tulane Faculty Practice
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
Tulane Faculty Practice
mi
from
New Orleans, LA
Click here to add this to my saved trials
Preventing Sexual Dysfunction With Aromatase Inhibitors
Preventing Sexual Dysfunction in Women on Aromatase Inhibitors
Status: Enrolling
Updated:  3/13/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Preventing Sexual Dysfunction With Aromatase Inhibitors
Preventing Sexual Dysfunction in Women on Aromatase Inhibitors
Status: Enrolling
Updated: 3/13/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
AMPM Research Clinic
mi
from
Miami, FL
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
AMPM Research Clinic
mi
from
Miami, FL
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
Illinois Cancer Care
mi
from
Peoria, IL
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated:  3/14/2017
Commonwealth Hematology-Oncology
mi
from
Lawrence, MA
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Status: Enrolling
Updated: 3/14/2017
Commonwealth Hematology-Oncology
mi
from
Lawrence, MA
Click here to add this to my saved trials
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  3/20/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 3/20/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  3/20/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 3/20/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)
Evaluation of Molecular Breast Imaging in Patients With a High Likelihood of Ductal Carcinoma in Situ
Status: Enrolling
Updated:  3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)
Evaluation of Molecular Breast Imaging in Patients With a High Likelihood of Ductal Carcinoma in Situ
Status: Enrolling
Updated: 3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated:  3/21/2017
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated: 3/21/2017
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated:  3/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated: 3/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated:  3/21/2017
Stanford Hospitals and Clinics
mi
from
Stanford, CA
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated: 3/21/2017
Stanford Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Univ Of Al At Birmingham
mi
from
Birmingham, AL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Univ Of Al At Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Illinois Cancercare, Pc
mi
from
Peoria, IL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Illinois Cancercare, Pc
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Oncology Care Associates, P.A.
mi
from
Wheaton, MD
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Oncology Care Associates, P.A.
mi
from
Wheaton, MD
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Presbyterian Hospital Cancer Research
mi
from
Charlotte, NC
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Presbyterian Hospital Cancer Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
University of Wisconsin
mi
from
Madison, WI
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Mayo Clinic
mi
from
Jacksonville, FL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials